Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series.


Journal

Case reports in nephrology
ISSN: 2090-6641
Titre abrégé: Case Rep Nephrol
Pays: United States
ID NLM: 101598418

Informations de publication

Date de publication:
2019
Historique:
received: 11 06 2019
revised: 01 08 2019
accepted: 12 08 2019
entrez: 6 11 2019
pubmed: 7 11 2019
medline: 7 11 2019
Statut: epublish

Résumé

Idiopathic nephrotic syndrome (INS) represents 15%-30% of adulthood glomerulopathies. Corticosteroids have been the main treatment for decades and are effective in 70% of minimal-change disease patients and ~30% of focal segmental glomerulosclerosis patients. Multidrug-resistant (steroids, calcineurin-inhibitors, cyclophosphamide, mycophenolate-mofetil, rituximab) idiopathic nephrotic syndrome is a major therapeutic challenge in nephrology. Apheresis (double-filtration plasmapheresis or semi specific immunoadsorption) could act by eliminating the circulating factor (apolipoproteinA1b, solubleCD40L, suPAR) increasing glomerular permeability seen in INS. The aim of the study was to report the outcome of three patients with multidrug-resistant INS treated successfully with apheresis.

Identifiants

pubmed: 31687235
doi: 10.1155/2019/7304786
pmc: PMC6803719
doi:

Types de publication

Case Reports

Langues

eng

Pagination

7304786

Informations de copyright

Copyright © 2019 Hamza Naciri Bennani et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Clin Exp Nephrol. 2014 Apr;18(2):286-90
pubmed: 24535024
Sci Transl Med. 2014 Oct 1;6(256):256ra136
pubmed: 25273097
Acta Paediatr. 2019 Apr;108(4):757-762
pubmed: 30230027
Med Sci (Paris). 2008 Oct;24(10):853-8
pubmed: 18950582
Pediatr Nephrol. 2019 Oct;34(10):1655-1669
pubmed: 30218191
J Am Soc Nephrol. 2013 Apr;24(5):702-11
pubmed: 23431071
Nephron Extra. 2015 Aug 29;5(2):58-66
pubmed: 26557843
J Am Soc Nephrol. 2012 Nov;23(11):1769-76
pubmed: 22997260
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):911-913
pubmed: 30952629
Transpl Int. 2012 May;25(5):e62-6
pubmed: 22409658
J Autoimmun. 2018 May;89:149-161
pubmed: 29307588

Auteurs

Hamza Naciri Bennani (H)

Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, Grenoble, France.

Thomas Jouve (T)

Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, Grenoble, France.
Université Grenoble Alpes, Grenoble, France.

Johan Noble (J)

Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, Grenoble, France.
Université Grenoble Alpes, Grenoble, France.

Lionel Rostaing (L)

Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, Grenoble, France.
Université Grenoble Alpes, Grenoble, France.

Paolo Malvezzi (P)

Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, Grenoble, France.

Rachel Tetaz (R)

Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, Grenoble, France.

Classifications MeSH